Adetunji Toriola, MD, PhD

Research Interest

Dr. Toriola’s research focuses on characterizing the molecular basis, and determinants of mammographic breast density and breast cancer in order to identify those that can be targeted in breast cancer prevention, especially in premenopausal women. He is the Principal Investigator on 2 R01s (R37CA23560, R01CA246592) in this research area. One of these is a phase II clinical trial investigating the effect of RANKL inhibition on mammographic breast density and breast tissue/blood markers in premenopausal women with dense breasts (R37CA235602: https://clinicaltrials.gov/ct2/show/NCT04067726). The second study uses state of the art metabolomics platforms to interrogate the metabolite profiles of mammographic breast density in premenopausal women (R01CA246592). In addition, he performs molecular epidemiologic studies on colorectal and pancreatic cancers, evaluating the utility of biomarkers to investigate the associations of energetics, and inflammation with risk/mortality. He is MPI on the ColoCare Study (U01CA206110), a large multicenter cohort of colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes.

Education

• 1998: MD, Obafemi Awolowo University, Ile-Ife, Nigeria
• 2007: MPH, University of Kuopio, Kuopio, Finland
• 2011: PhD, epidemiology, University of Tampere, Tampere, Finland

Training

• 2011 - 2012: Fellow, German Cancer Research Center, Heidelberg, Germany

Journal Articles

Disclaimer: This listing may not include all articles associated with this physician and may include publications related to other physicians with a similar name.